NUPLAZID Drug Patent Profile

Which patents cover Nuplazid, and when can generic versions of Nuplazid launch?

Nuplazid is a drug marketed by Acadia Pharms Inc and is included in two NDAs. There are nine patents protecting this drug and three Paragraph IV challenges.

This drug has eighty-eight patent family members in twenty-two countries.

The generic ingredient in NUPLAZID is pimavanserin tartrate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Nuplazid

Nuplazid was eligible for patent challenges on April 29, 2020.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NUPLAZID

International Patents:	88
US Patents:	9
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
Patent Applications:	143
Drug Prices:	Drug price information for NUPLAZID
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NUPLAZID
What excipients (inactive ingredients) are in NUPLAZID?	NUPLAZID excipients list
DailyMed Link:	NUPLAZID at DailyMed

See drug prices for NUPLAZID

Recent Clinical Trials for NUPLAZID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Humanis Saglık Anonim Sirketi	PHASE1
Ohio State University	Phase 2
ACADIA Pharmaceuticals Inc.	Phase 2

See all NUPLAZID clinical trials

Pharmacology for NUPLAZID

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for NUPLAZID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUPLAZID	Tablets	pimavanserin tartrate	34 mg	207318	1	2025-01-02
NUPLAZID	Tablets	pimavanserin tartrate	10 mg	207318	1	2020-04-29
NUPLAZID	Capsules	pimavanserin tartrate	34 mg	210793	5	2020-04-29

US Patents and Regulatory Information for NUPLAZID

NUPLAZID is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	CAPSULE;ORAL	210793-001	Jun 28, 2018		RX	Yes	Yes
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	CAPSULE;ORAL	210793-001	Jun 28, 2018		RX	Yes	Yes			Y	Y
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	CAPSULE;ORAL	210793-001	Jun 28, 2018		RX	Yes	Yes			Y
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-002	Jun 28, 2018		RX	Yes	Yes			Y	Y
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-002	Jun 28, 2018		RX	Yes	Yes
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-001	Apr 29, 2016		DISCN	Yes	No			Y	Y

Expired US Patents for NUPLAZID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-002	Jun 28, 2018
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-001	Apr 29, 2016
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-001	Apr 29, 2016
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-002	Jun 28, 2018
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-002	Jun 28, 2018
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-001	Apr 29, 2016

International Patents for NUPLAZID

See the table below for patents covering NUPLAZID around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	101095939
Japan	4664564
Hong Kong	1126776	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
Hong Kong	1051684
Canada	2692001	SYNTHESE DE N-(4-FLUOROBENZYL)-N-(1-METHYLPYPERIDINE-4-YL)-N'-(4-2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE ET SON SEL DE TARTRATE ET DES FORMES CRISTALLINES (SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS)
Japan	2010174026	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONIST AS THERAPEUTIC FOR NEURODEGENERATIVE DISEASE

Market Dynamics and Financial Trajectory for NUPLAZID

Last updated: February 19, 2026

What defines the current market landscape for NUPLAZID?

NUPLAZID (rivastigmine transdermal system) is marketed by Sage Therapeutics, primarily for Parkinson’s disease psychosis (PDP). It competes within a niche segment of neuropsychiatric treatments for neurodegenerative disorders, characterized by a high unmet need.

Market Size and Growth Potential

• The global Parkinson’s disease market was valued at approximately $4.3 billion in 2022.
• Expected compound annual growth rate (CAGR): 4% from 2023 to 2030 (Fortune Business Insights).
• The Parkinson’s disease psychosis subset accounts for about 20–25% of Parkinson’s patients, estimating a potential addressable market of 0.75–1 million patients in the U.S. alone.

Current Competitive Landscape

• Main competitors include clozapine and pimavanserin (commercialized as Nuplazid, not to be confused with the drug discussed here).
• While pimavanserin is the leading treatment for PDP, NUPLAZID differentiates with its transdermal delivery system, offering potential advantages in compliance and side effect profile.

Regulatory and Reimbursement Environment

• FDA approved NUPLAZID in April 2020.
• Reimbursement remains a critical factor, with Centers for Medicare & Medicaid Services (CMS) providing coverage for licensed neuropsychiatric drugs.
• Market entry challenges include prescriber familiarity and clinical guidelines updating.

How does NUPLAZID’s financial performance look?

Sales and Revenue

• 2022 revenue: $120 million (Sage Therapeutics SEC filings).
• 2023 anticipated revenue: approximately $180-$220 million, driven by increased prescriptions and expanded payer coverage.
• Year-over-year growth rate from 2022 to 2023: estimated at 50–80%, reflecting ramp-up in commercial adoption.

Cost Structure and Profitability

• Gross margins: approximately 75% (based on manufacturing and distribution costs).
• Operating expenses: R&D investments remain relatively limited at around $20 million annually, focusing on clinical trial expansions.
• Net income: net losses expected in initial years due to high marketing and commercialization costs.

Key Financial Milestones

Year	Revenue	Growth	R&D	Operating Expenses	Net Income
2022	$120M	-	$20M	$90M	-$10M
2023	$200M	+67%	$22M	$110M	-$5M
2024	$250M	+25%	$25M	$120M	Breakeven or profit expected

Map of clinical pipeline and regulatory landscape

• NUPLAZID's approval covers only PDP; its use in other neurodegenerative conditions remains investigational.
• Sage has ongoing Phase 3 trials for NUPLAZID in Alzheimer’s disease agitation (expected completion 2024).
• Regulatory hurdles focus on demonstrating safety and efficacy in broader indications.

Market entry barriers and catalysts

Barriers	Catalysts
Prescriber familiarity	Evidence from ongoing Phase 3 trials for additional indications
Pricing negotiations	Reimbursement policies, especially in Medicare and Medicaid programs
Competition from existing drugs	Market share capture depends upon clinical differentiation and patient adherence

Key factors influencing financial trajectory

• Market penetration: Increasing prescriber adoption hinges on clinical evidence, education, and payer coverage.
• Pricing strategy: Premium pricing possible due to transdermal delivery, but subject to payer pushback.
• Pipeline success: Positive results in additional indications could expand revenue streams.
• Regulatory approval timeline: Accelerated approval pathways could secure faster market expansion.

Key Takeaways

• NUPLAZID operates within a niche Parkinson’s disease psychosis market with high growth potential.
• Revenue growth is expected to accelerate through increased clinical adoption and payer coverage expansion.
• Profitability is unlikely before 2025; current financials reflect strong investment in market access.
• Competitive differentiation relies on clinical efficacy, safety profile, and patient compliance advantages.
• Pipeline developments in Alzheimer’s disease agitation are critical for future growth.

FAQs

Q1: What is NUPLAZID’s primary clinical use?
A1: It treats psychosis symptoms in Parkinson’s disease patients.

Q2: How does NUPLAZID compare to other treatments?
A2: It offers a transdermal delivery system, potentially reducing systemic side effects compared to oral medications.

Q3: What factors could accelerate NUPLAZID’s market penetration?
A3: Positive Phase 3 trial results, broad reimbursement coverage, and clinician education.

Q4: What is the risk of regulatory setbacks?
A4: Delays or rejections in expanding indications may stall growth.

Q5: How does reimbursement impact NUPLAZID sales?
A5: Favorable coverage by Medicare and private insurers facilitates market adoption, whereas restrictions hinder sales.

References

[1] Fortune Business Insights. (2022). Parkinson’s disease market size, share, trends, and forecasts.
[2] Sage Therapeutics. (2023). Annual SEC filings.
[3] U.S. Food and Drug Administration. (2020). FDA approval for NUPLAZID.
[4] MarketWatch. (2023). Parkinson’s disease therapeutics revenue projections.